Semaglutide Safe and Effective for Dialysis Patients with Type 2 Diabetes

Type 2 diabetes (T2D) is a global health crisis, often leading to severe complications like end-stage renal disease (ESRD), necessitating dialysis. Managing T2D in patients on dialysis is complex, as many standard treatments have altered pharmacokinetics or safety concerns in this vulnerable population. There has been a significant knowledge gap regarding the safety and efficacy of Semaglutide, a widely used GLP-1 receptor agonist, specifically in patients who have initiated dialysis.

The study found no significant increase in serious adverse events (SAEs) in the Semaglutide group compared to placebo, with SAE rates of 18.5% vs. 20.1% (p=0.32). Specifically, cardiovascular event rates were 3.2% in the Semaglutide group vs. 4.1% in the placebo group (p=0.18), and all-cause mortality was 2.8% vs. 3.5% (p=0.25). These findings indicate a comparable safety profile to non-dialysis populations. Furthermore, patients on Semaglutide showed a significant reduction in HbA1c (a measure of average blood sugar over 2-3 months) by 0.8% (p<0.001) and an average weight loss of 4.5 kg (p<0.001) compared to placebo, indicating maintained efficacy. The most critical finding was that Semaglutide treatment did not increase the risk of acute kidney injury or worsening renal function in patients already on dialysis, demonstrating its safety in this specific context.